Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

Br J Cancer · 2010 · PMC2966629 · PMID 20700118

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The anastrozole-based IMPACT and PROACT trials also showed a trend favouring the AI arm, although the results in comparison with tamoxifen were not statistically significant ( Smith et al , 2005 ; Cataliotti et al , 2006 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.